Curaleaf Holdings Inc.

CURLF-OTC

Analysis and Opinions about CURLF-OTC

Signal
Opinion
Expert
Chart
BUY
BUY
May 11, 2021
Until this week, Curaleaf was the leader in this space. Yesterday, True Leaf and Harvest merged to bump Curaleaf out of that spot in terms of EBITDA. That said, Curaleaf has done a great job executing in many U.S. states. They cultivate, producer and sell cannabis in dispensaries. Their profit margin is strong. This will be one of the fastest-growing sectors in the US and the world in the coming decade. The company has just bought into Europe and expanding their footprint to become a global producer. Shares have certainly pulled back. But it issued strong earnings today but markets are selling off today, so the stock price isn't up as much as it should be. He's happy to own it.
Show full opinionHide full opinion
Until this week, Curaleaf was the leader in this space. Yesterday, True Leaf and Harvest merged to bump Curaleaf out of that spot in terms of EBITDA. That said, Curaleaf has done a great job executing in many U.S. states. They cultivate, producer and sell cannabis in dispensaries. Their profit margin is strong. This will be one of the fastest-growing sectors in the US and the world in the coming decade. The company has just bought into Europe and expanding their footprint to become a global producer. Shares have certainly pulled back. But it issued strong earnings today but markets are selling off today, so the stock price isn't up as much as it should be. He's happy to own it.
TOP PICK
TOP PICK
May 4, 2021
His pick in cannabis (the complete opposite to Organigram). They're a Canadian company but they operate entirely in the U.S., and (after a recent $300 million purchase) five western European countries. In terms of cannabis legalization, Europe is roughly where the U.S. was three years ago. He alsolikes that they're vertically integrated with 23 cultivation sites, 24 processing ones, and 106 dispensaries with licenses to add 30 across 23 American states. He likes that they're leveraging their roots in medical MJ, branching into the bigger recreational market. They rise above other cannabis companies by offering good governance, sound strategy and executive ownership of shares. Checks all the boxes. (Analysts’ price target is $28.02)
Show full opinionHide full opinion
His pick in cannabis (the complete opposite to Organigram). They're a Canadian company but they operate entirely in the U.S., and (after a recent $300 million purchase) five western European countries. In terms of cannabis legalization, Europe is roughly where the U.S. was three years ago. He alsolikes that they're vertically integrated with 23 cultivation sites, 24 processing ones, and 106 dispensaries with licenses to add 30 across 23 American states. He likes that they're leveraging their roots in medical MJ, branching into the bigger recreational market. They rise above other cannabis companies by offering good governance, sound strategy and executive ownership of shares. Checks all the boxes. (Analysts’ price target is $28.02)
Brian Madden
Price
$14.840
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
March 5, 2021
Has pulled back recently. The whole marijuana sector who has had a huge move is taking a breather. Bought around $10. The pull-back is buyable. The geographic foot print, strategy and vertical integration is positive. They own growers, intermediate processors, and has good downstream footprint. The regulatory and social license backdrop is good with Biden and the democrats. Addressable market is huge.
Show full opinionHide full opinion
Has pulled back recently. The whole marijuana sector who has had a huge move is taking a breather. Bought around $10. The pull-back is buyable. The geographic foot print, strategy and vertical integration is positive. They own growers, intermediate processors, and has good downstream footprint. The regulatory and social license backdrop is good with Biden and the democrats. Addressable market is huge.
Brian Madden
Price
$0.000
Owned
Yes
TOP PICK
TOP PICK
January 7, 2021
Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)
Show full opinionHide full opinion
Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)
Brian Madden
Price
$0.000
Owned
Yes
BUY
BUY
December 8, 2020
It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.
Show full opinionHide full opinion
It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.
TOP PICK
TOP PICK
November 5, 2020
Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)
Show full opinionHide full opinion
Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)
Brian Madden
Price
$0.000
Owned
Yes
HOLD
HOLD
May 27, 2020
He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.
Show full opinionHide full opinion
He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.
BUY
BUY
April 4, 2019
CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.
Show full opinionHide full opinion
CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.
Showing 1 to 8 of 8 entries
  • «
  • 1
  • »

Curaleaf Holdings Inc.(CURLF-OTC) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Curaleaf Holdings Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Curaleaf Holdings Inc.(CURLF-OTC) Frequently Asked Questions

What is Curaleaf Holdings Inc. stock symbol?

Curaleaf Holdings Inc. is a American stock, trading under the symbol CURLF-OTC on the US OTC (CURLF). It is usually referred to as OTC:CURLF or CURLF-OTC

Is Curaleaf Holdings Inc. a buy or a sell?

In the last year, 4 stock analysts published opinions about CURLF-OTC. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Curaleaf Holdings Inc..

Is Curaleaf Holdings Inc. a good investment or a top pick?

Curaleaf Holdings Inc. was recommended as a Top Pick by Bruce Campbell (2) on 2021-05-11. Read the latest stock experts ratings for Curaleaf Holdings Inc..

Why is Curaleaf Holdings Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Curaleaf Holdings Inc. worth watching?

4 stock analysts on Stockchase covered Curaleaf Holdings Inc. In the last year. It is a trending stock that is worth watching.

What is Curaleaf Holdings Inc. stock price?

On 2021-05-14, Curaleaf Holdings Inc. (CURLF-OTC) stock closed at a price of $14.4.